Last reviewed · How we verify
Sacubitril and Valsartan-Reference product
At a glance
| Generic name | Sacubitril and Valsartan-Reference product |
|---|---|
| Sponsor | Humanis Saglık Anonim Sirketi |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Bioequivalence Study to Compare Sacubitril and Valsartan Tablets (97mg/103mg) Versus Entresto® (Sacubitril and Valsartan) Tablets (97 mg/103 mg) (PHASE1)
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions (PHASE1)
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions (PHASE1)
- Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets (PHASE1)
- A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions (PHASE1)
- Replication of the PARADIGM-HF Heart Failure Trial in Healthcare Claims Data.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: